Alkermes to Acquire Rodin Therapeutics for $950M

 Alkermes to Acquire Rodin Therapeutics for $950M


  • Alkermes acquires Rodin in all cash transaction, making the total deal value as $950M which include $100M upfront in cash and up to $850M as clinical, regulatory and commercial milestones. The transaction is expected to be completed by the end of Nov’2019
  • The acquisition will lead to the expansion of Alkermes’ Presence in CNS to a wide range of neurodegenerative disorders by leveraging Rodin’s synaptogenic platform
  • Alkermes plans to advance IND activities for Rodin’s preclinical portfolio, prioritizing its clinical candidates and intends to continue Rodin’s preclinical research program focusing the subset of frontotemporal dementia patients with an inherited mutation of the progranulin gene (FTD-GRN) along with its work in hematology & oncology

Click here to­ read full press release/ article | Ref: Rodin Therapeutics  | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post